Nervous System Diseases
Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.
Subtype terms (17)
More specific conditions that are subtypes of Nervous System Diseases in the MeSH hierarchy.
- Autoimmune Diseases of the Nervous System
26 drugs (16 approved, 10 experimental)
- Autonomic Nervous System Diseases
48 drugs (36 approved, 12 experimental)
- Central Nervous System Diseases
87 drugs (55 approved, 32 experimental)
- Chronobiology Disorders
13 drugs (6 approved, 7 experimental)
- Cranial Nerve Diseases
4 drugs (3 approved, 1 experimental)
- Demyelinating Diseases
22 drugs (15 approved, 7 experimental)
- Nervous System Malformations
6 drugs approved
- Nervous System Neoplasms
7 drugs (4 approved, 3 experimental)
- Neurocutaneous Syndromes
- Neurodegenerative Diseases
73 drugs (28 approved, 45 experimental)
- Neuroinflammatory Diseases
13 drugs (6 approved, 7 experimental)
- Neurologic Manifestations
18 drugs (14 approved, 4 experimental)
- Neuromuscular Diseases
27 drugs (16 approved, 11 experimental)
- Neurotoxicity Syndromes
14 drugs (12 approved, 2 experimental)
- Restless Legs Syndrome
47 drugs (36 approved, 11 experimental)
- Sleep Wake Disorders
99 drugs (72 approved, 27 experimental)
- Trauma, Nervous System
7 drugs (6 approved, 1 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (14)
Phase 3 trials (16)
Phase 2 trials (25)
- roflumilast
- melatonin
- methylprednisolone
- Rolipram
- ketamine
- tenecteplase
- pembrolizumab
- fluoxetine
- sodium phenylbutyrate
- propranolol
- Tasadenoturev
- rotigotine
- Ursodoxicoltaurine
- tianeptine
- alteplase
- finasteride
- testosterone
- ferumoxytol
- aripiprazole
- Cerebral Dopamine Neurotrophic Factor
- olive
- xpro1595
- autologous adipose-derived mesenchymal stem cells
- etidronate
- aoc 1001
Phase 1 trials (16)
Organizations
Organization Involved with Phase 4 Indications (23)
- Gilead Sciences
- Merck Serono
- National Institute of Mental Health (NIMH)
- Cardiovascular Institute of the South Clinical Research Corporation
- Chulalongkorn University
- King Fahad Medical City
- McMaster University
- University of Toronto
- Capital Medical University
- Peking University
- State University of New York
- University of California, San Diego
- University of Modena and Reggio Emilia
- University of Lille
- Karolinska Institute
- Government of China
- Catholic University of Korea
- Baird Multiple Sclerosis Center
- University of Western Australia
- University of Western Ontario
- University of Campania Luigi Vanvitelli
- University of Antwerp
- Dalarna County Council, Sweden
Organization Involved with Phase 3 Indications (27)
- Shire
- Bracco
- Guerbet
- Pfizer
- Ipsen
- Bayer
- Bonn Education Association for Dietetics r.A., Cologne, Germany
- Erydel
- Merz
- PTC Therapeutics
- Xenon Pharmaceuticals Inc.
- Otsuka
- Kyberg Vital GmbH
- Cornell University
- University of Washington
- Tufts University
- University of Malaya
- Columbia University
- Vanderbilt University
- Icahn School of Medicine at Mount Sinai
- Tonix Pharmaceuticals
- KPJ Tawakkal Health Centre
- Isfahan University
- NeurogesX
- Department of Health and Human Services
- Lundbeck
- Johnson and Johnson
Organization Involved with Phase 2 Indications (66)
- AC Immune SA
- Chelsea Therapeutics
- Savient Pharmaceuticals
- Spectrum Pharmaceuticals
- Celgene
- Merck
- Eli Lilly
- Amylyx Pharmaceuticals Inc.
- Baxalta
- Bellus Health Inc
- DNAtrix, Inc.
- FORUM Pharmaceuticals Inc
- Herantis Pharma Plc.
- INC Research
- Boehringer Ingelheim
- Capricor Inc.
- Renovis
- Fundación Pública Andaluza
- North Florida Foundation for Research and Education
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Center for Research Resources (NCRR)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of Roma La Sapienza
- Baylor University
- Centre Hospitalier de PAU
- Harvard University
- Eastern Virginia Medical School
- Emory University
- +36 more
Organization Involved with Phase 1 Indications (17)
- AbbVie
- Actelion
- Corestem, Inc.
- IASO Pharma Inc.
- SRI International
- Voyager Therapeutics
- Chong Kun Dang Pharmaceutical
- United States Army
- Huazhong University of Science and Technology
- Hanyang University
- Johns Hopkins University
- Neurogen Brain and Spine Institute
- University of Michigan
- Chonbuk National University
- University of Texas at Houston
- Pacific Research Network, Inc.
- University of Alabama, Birmingham
Organization Involved with Other Experimental Indications (18)
- Vitaflo
- Advanced Peptides
- International Atomic Energy Agency
- University of London
- University of Hawaii
- University of Oklahoma
- Istanbul University
- Netherlands Organisation for Scientific Research
- University of Copenhagen
- Leiden University
- Greenwood Genetic Center
- University of Montpellier
- Rush University
- University of Ljubljana
- University of Paris
- European Commission
- Necmettin Erbakan University
- University Clermont Auvergne